Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2026)
Castle Biosciences (CSTL) posted Cash from Financing Activities of -$886000.0 for Q2 2026, up 82.4% sequentially from -$5.0 million in Q1 2026, and down 977.23% YoY from $101000.0 in Q2 2025.
Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Castle Biosciences has reported Cash from Financing Activities for 9 years, with the latest figure at -$886000.0 in Q2 2026.
- Quarterly Cash from Financing Activities fell 977.23% year-over-year to -$886000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$11.4 million (down 90.48% YoY) and the FY2025 annual result came in at -$7.0 million, down 213.37% from the prior year.
- Cash from Financing Activities improved to -$886000.0 in Q2 2026 per CSTL's latest filing, from -$5.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.6 million in Q1 2024 and troughed at -$5.4 million in Q4 2024.
- A 5-year average of -$417944.4 and a median of $43500.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities surged 1762.22% in 2024, then slumped 977.23% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$750000.0 in 2022, then sank by 339.6% to -$3.3 million in 2023, then slumped by 63.33% to -$5.4 million in 2024, then advanced by 14.78% to -$4.6 million in 2025, then jumped by 80.69% to -$886000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$886000.0, -$5.0 million, and -$4.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | -1.57 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 7.27 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | -325.19 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | -144.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | -214.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 3.76 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | -129.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | -317.75 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | -229.00 Mn |
| 10 | Castle Biosciences | 926.56 Mn | 659.75 Mn | 79.85 Mn | -886,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -886,000.00 |
| Jun 30, 2026 | -886,000.00 |
| Mar 31, 2026 | -5.03 Mn |
| Mar 31, 2026 | -5.03 Mn |
| Dec 31, 2025 | -4.59 Mn |
| Dec 31, 2025 | -4.59 Mn |
| Sep 30, 2025 | -919,000.00 |
| Sep 30, 2025 | -919,000.00 |
| Jun 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 101,000.00 |
| Mar 31, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Sep 30, 2024 | 838,000.00 |
| Sep 30, 2024 | 838,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Mar 31, 2024 | 10.64 Mn |
| Mar 31, 2024 | 10.64 Mn |